Iranian Journal of Radiology

Published by: Neoscriber Demo Publisher
Crossmark

Assessment of Treatment Efficacy Immediately After Combined Therapy of Ultrasound-Guided Radiofrequency Ablation and Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison Between Multidetector-Row CT and MRI

Sung Mo Kim 1 , Sang Soo Shin ORCID 1 , 2 , * , Byung Chan Lee 1 , Jin Woong Kim 3 , Suk Hee Heo 1 , Chung Hwan Jun 4 and Yong Yeon Jeong 1
Authors Information
1 Department of Radiology, Chonnam National University Hospital and Medical School, Gwangju, South Korea
2 Center for Aging and Geriatrics, Chonnam National University Hospital and Medical School, Gwangju, South Korea
3 Department of Radiology, Chosun University Hospital, Gwangju, South Korea
4 Department of Gastroenterology, Chonnam National University Hospital and Medical School, Gwangju, South Korea
Article information
  • Iranian Journal of Radiology: April 30, 2019, 16 (2); e80926
  • Published Online: April 30, 2019
  • Article Type: Research Article
  • Received: June 17, 2018
  • Revised: December 10, 2018
  • Accepted: February 10, 2019
  • DOI: 10.5812/iranjradiol.80926

To Cite: Kim S M, Shin S S, Lee B C, Kim J W, Heo S H, et al. Assessment of Treatment Efficacy Immediately After Combined Therapy of Ultrasound-Guided Radiofrequency Ablation and Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison Between Multidetector-Row CT and MRI, Iran J Radiol. 2019 ; 16(2):e80926. doi: 10.5812/iranjradiol.80926.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors. J Hepatol. 2013;58(1):89-97. doi: 10.1016/j.jhep.2012.09.020. [PubMed: 23023009].
  • 2. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569-77. quiz 578. doi: 10.1038/ajg.2011.425. [PubMed: 22158026]. [PubMed Central: PMC3321437].
  • 3. Giannini EG, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnu L, et al. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: An Italian experience. Am J Gastroenterol. 2012;107(10):1588-9. author reply 1590. doi: 10.1038/ajg.2012.250. [PubMed: 23034617].
  • 4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. [PubMed: 22353262].
  • 5. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47(1):82-9. doi: 10.1002/hep.21933. [PubMed: 18008357].
  • 6. Kim JW, Shin SS, Heo SH, Hong JH, Lim HS, Seon HJ, et al. Ultrasound-guided percutaneous radiofrequency ablation of liver tumors: How we do it safely and completely. Korean J Radiol. 2015;16(6):1226-39. doi: 10.3348/kjr.2015.16.6.1226. [PubMed: 26576111]. [PubMed Central: PMC4644743].
  • 7. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, et al. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg Oncol. 2008;17(1):23-31. doi: 10.1016/j.suronc.2007.08.002. [PubMed: 17869095].
  • 8. Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: Analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol. 2008;190(6):1544-51. doi: 10.2214/AJR.07.2798. [PubMed: 18492905].
  • 9. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195(3):758-65. doi: 10.2214/AJR.09.2954. [PubMed: 20729457].
  • 10. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: Correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188(2):480-8. doi: 10.2214/AJR.05.2079. [PubMed: 17242258].
  • 11. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors. Eur J Radiol. 2006;59(3):432-41. doi: 10.1016/j.ejrad.2006.03.007. [PubMed: 16690240].
  • 12. Zhong-Zhen S, Kai L, Rong-Qin Z, Er-Jiao X, Ting Z, Ao-Hua Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. Ultraschall Med. 2012;33(7):E250-5. doi: 10.1055/s-0032-1325466. [PubMed: 23238803].
  • 13. Lee HJ, Kim JW, Hur YH, Shin SS, Heo SH, Cho SB, et al. Combined therapy of transcatheter arterial chemoembolization and radiofrequency ablation versus surgical resection for single 2-3 cm hepatocellular carcinoma: A propensity-score matching analysis. J Vasc Interv Radiol. 2017;28(9):1240-1247 e3. doi: 10.1016/j.jvir.2017.05.015. [PubMed: 28688816].
  • 14. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2-3 cm in diameter: Transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81(3):e189-93. doi: 10.1016/j.ejrad.2011.01.122. [PubMed: 21353417].
  • 15. Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18(6):1624-9. doi: 10.1245/s10434-011-1673-8. [PubMed: 21445671].
  • 16. Yamanaka T, Yamakado K, Takaki H, Nakatsuka A, Shiraki K, Hasegawa H, et al. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol. 2012;30(7):553-9. doi: 10.1007/s11604-012-0087-2. [PubMed: 22610876].
  • 17. Koda M, Tokunaga S, Okamoto T, Hodozuka M, Miyoshi K, Kishina M, et al. Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2015;63(6):1360-7. doi: 10.1016/j.jhep.2015.07.023. [PubMed: 26232269].
  • 18. Kim KW, Lee JM, Klotz E, Kim SJ, Kim SH, Kim JY, et al. Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol. 2011;196(5):W565-72. doi: 10.2214/AJR.10.5122. [PubMed: 21512046].
  • 19. Bouda D, Lagadec M, Alba CG, Barrau V, Dioguardi Burgio M, Moussa N, et al. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly. J Magn Reson Imaging. 2016;44(5):1070-90. doi: 10.1002/jmri.25369. [PubMed: 27505619].
  • 20. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):532-40. doi: 10.1007/s00270-009-9728-y. [PubMed: 19847482].
  • 21. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression. J Gastroenterol. 2013;48(11):1283-92. doi: 10.1007/s00535-012-0747-0. [PubMed: 23338488].
  • 22. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol. 2012;81(10):2730-6. doi: 10.1016/j.ejrad.2011.11.013. [PubMed: 22137612].
  • 23. Koda M, Tokunaga S, Fujise Y, Kato J, Matono T, Sugihara T, et al. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol. 2012;81(7):1400-4. doi: 10.1016/j.ejrad.2011.03.004. [PubMed: 21440397].
  • 24. Yoon JH, Lee EJ, Cha SS, Han SS, Choi SJ, Juhn JR, et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol. 2010;21(3):348-56. doi: 10.1016/j.jvir.2009.11.014. [PubMed: 20116285].
  • 25. Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore). 2017;96(3). e5518. doi: 10.1097/MD.0000000000005518. [PubMed: 28099329]. [PubMed Central: PMC5279074].
  • 26. De Santis M, Alborino S, Tartoni PL, Torricelli P, Casolo A, Romagnoli R. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol. 1997;7(1):10-6. [PubMed: 9000387].
  • 27. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (liver imaging reporting and data system): Summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology. 2015;61(3):1056-65. doi: 10.1002/hep.27304. [PubMed: 25041904].
  • 28. Yoon JH, Park JW, Lee JM. Noninvasive diagnosis of hepatocellular carcinoma: elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea practice guidelines compared with other guidelines and remaining issues. Korean J Radiol. 2016;17(1):7-24. doi: 10.3348/kjr.2016.17.1.7. [PubMed: 26798212]. [PubMed Central: PMC4720815].
  • 29. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: Key pathologic and imaging aspects. Radiology. 2014;272(3):635-54. doi: 10.1148/radiol.14132361. [PubMed: 25153274]. [PubMed Central: PMC4263631].
  • 30. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30-50. doi: 10.1148/radiol.14132362. [PubMed: 25247563]. [PubMed Central: PMC4263770].
  • 31. Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: Initial experience. AJR Am J Roentgenol. 2008;190(1):91-8. doi: 10.2214/AJR.07.2384. [PubMed: 18094298].
  • 32. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014;273(1):241-60. doi: 10.1148/radiol.14132958. [PubMed: 24927329]. [PubMed Central: PMC4263618].
  • 33. Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, et al. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma. Abdom Imaging. 2015;40(1):102-11. doi: 10.1007/s00261-014-0201-2. [PubMed: 25052767].
  • 34. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425-34. doi: 10.3348/kjr.2009.10.5.425. [PubMed: 19721826]. [PubMed Central: PMC2731859].
  • 35. Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20(15):4160-6. doi: 10.3748/wjg.v20.i15.4160. [PubMed: 24764654]. [PubMed Central: PMC3989952].
  • 36. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: A proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol. 2011;46(12):1418-26. doi: 10.1007/s00535-011-0452-4. [PubMed: 21845378].
  • 37. Kawamoto C, Yamauchi A, Baba Y, Kaneko K, Yakabi K. Measurement of intrahepatic pressure during radiofrequency ablation in porcine liver. J Gastroenterol. 2010;45(4):435-42. doi: 10.1007/s00535-009-0156-1. [PubMed: 19936601].
  • 38. Khankan AA, Murakami T, Onishi H, Matsushita M, Iannaccone R, Aoki Y, et al. Hepatocellular carcinoma treated with radio frequency ablation: An early evaluation with magnetic resonance imaging. J Magn Reson Imaging. 2008;27(3):546-51. doi: 10.1002/jmri.21050. [PubMed: 18183580].
  • 39. Kim YS, Rhim H, Lim HK, Choi D, Lee MW, Park MJ. Coagulation necrosis induced by radiofrequency ablation in the liver: histopathologic and radiologic review of usual to extremely rare changes. Radiographics. 2011;31(2):377-90. doi: 10.1148/rg.312105056. [PubMed: 21415185].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments